Follow-The-Filings

Security · featured owners

VRCA Verrica Pharmaceuticals Inc.

Health Care COM SHS Equity as of 2026 Q2 among managers we track

  • 1 Owner
  • Max 0.0%
  • $145K
  • 1 reduce

Who owns this now

Largest portfolio weights among featured holders · max 0.0% (Nathan Fischel - Dafna Capital Management) · not free-float ownership

  1. Nathan Fischel reduce 0.03%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
Nathan Fischel - Dafna Capital Management 2026 Q2 0.03% Reduce −84.5% 23,750 $145K history

1 current · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $5.12M $7.57M —
Gross profit * $4.62M $4.97M —
Gross margin * 90.2% 65.6% —
Net income -$67M -$76.58M -$17.89M
Net margin * -1307.5% -1012.1% —

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $77.53M $51.18M $42.54M
Total non-current assets * $4.07M $2.96M $4.59M
Total assets $81.6M $54.13M $47.13M
Total current liabilities $17.02M $29.01M $16.44M
Total non-current liabilities * $44.81M $34.98M $5.95M
Total equity $19.76M -$9.86M $24.74M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$38.58M -$60.93M -$17.63M
Cash from investing -$362,000 -$19,000 $0.00
Cash from financing $74.21M $37.73M $1.44M
Net change in cash $35.27M -$23.22M -$16.18M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders